Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

A pair of FDA-approved cancer drugs may help reverse the biological changes that drive Alzheimer’s disease, according to a ...

The money will support dozens of different approaches for improving women’s health, from new medicines to prevent maternal ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

About 20 million Americans have macular degeneration – a condition that damages vision and can cause blindness. Now, a doctor ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...